Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
NR

NASDAQ · NRXS

NeurAxis, Inc.

Healthcare · Biotechnology

$7.13

Down-$0.42 (-5.56%)

Updated Nov 2, 2026, 9:05 AM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
28.12M
P/E ratio
-3.46
Dividend yield
0.00%
52-week range
$2.21 – $9.33
Volume
150.39K
Avg. volume
388.77K

Price performance · NRXS

NRXS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

NRXS closed at $7.13 after 20 trading sessions, down 0.28% for the selected period.

Last close
$7.13
Period change
-0.28%
Period low
$6.50
Period high
$7.92
Daily close
View OHLC price history
NRXS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$7.49$7.49$7.02$7.13150.39K
Oct 29, 2026$7.65$7.735$7.4235$7.5590.58K
Oct 28, 2026$7.30$7.59$7.17$7.5773.28K
Oct 27, 2026$7.31$7.60$7.31$7.3638.92K
Oct 26, 2026$7.39$7.5079$7.25$7.2584.85K
Oct 23, 2026$7.57$7.68$7.36$7.4075.21K
Oct 22, 2026$7.87$7.87$7.44$7.6086.95K
Oct 21, 2026$7.84$8.05$7.715$7.9266.94K
Oct 20, 2026$7.86$8.00$7.75$7.8257.88K
Oct 19, 2026$7.72$7.94$7.24$7.85194.23K
Oct 16, 2026$7.66$7.82$7.40$7.70229.38K
Oct 15, 2026$6.87$7.84$6.80$7.741.13M
Oct 14, 2026$6.44$6.635$6.00$6.53173.09K
Oct 13, 2026$6.65$6.75$6.40$6.50118.08K
Oct 12, 2026$6.86$6.86$6.55$6.7274.64K
Oct 9, 2026$6.96$7.05$6.79$6.9356.73K
Oct 8, 2026$6.81$6.99$6.67$6.7730.01K
Oct 7, 2026$6.72$7.035$6.60$6.8366.06K
Oct 6, 2026$7.20$7.31$6.76$6.7866.54K
Oct 5, 2026$7.15$7.40$7.065$7.1553.78K

Latest NRXS news

The latest Smart Investors Daily articles mentioning NRXS.

Stock researchCompany · Overview

NRXS research

Overview

Company profile and research snapshot.

Company profile

Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.00
Implied upside
—
Analysts
8
NRXS recent ratings
DateFirmRatingTarget
Mar 20, 2026Craig-HallumBuy—
Dec 22, 2025Craig-HallumBuy—
Jun 16, 2025Craig-HallumBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026

CARMEL, Ind., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its third quarter period ended September 30, 2026, on Monday, November 9, 2026, before market open. The Company has scheduled a conference call for the same day, Monday, November 9, 2026, at 9:00

Yahoo · Oct 15, 2026

NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives

Total national coverage footprint for PENFS increases to over 147 million covered livesCARMEL, Ind., Oct. 15, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”). The co

Yahoo · Sep 29, 2026

NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer

CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer. In this role, Mr. Blanchard will oversee the Company’s commercial functions, including sales and marketing. The appointment of Mr. Blanchard as Chief Commercial Officer

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By